HMS Holdings Corp. HMSY reported adjusted earnings per share (EPS) of 27 cents in fourth-quarter 2019, which lagged the Zacks Consensus Estimate of 31 cents by 12.9%. Further, the bottom line declined 12.9% from the year-ago quarter.
Revenues of $163.4 million missed the Zacks Consensus Estimate by 4.4%. However, the top line improved 4.9% on a year-over-year basis.
2019 at a Glance
In 2019, the company reported revenues worth $626.4 million, which improved 4.7% from the previous year.
Adjusted EPS for the year was $1.12, up 7.7% from the previous year.
HMS Holdings Corp Price, Consensus and EPS Surprise
HMS Holdings Corp price-consensus-eps-surprise-chart | HMS Holdings Corp Quote
Q4 Segmental Analysis by Product
Revenues at this segment were $65 million in the fourth quarter, up 14.2% year over year.
Within Analytical Services, PI revenues (excluding Medicare RAC) amounted to $48.4 million, up 18.3% year over year.
PHM revenues totaled $16.6 million in the quarter under review, up 3.8% on a year-over-year basis.
Revenues at the Coordination of Benefits (COB) segment amounted to $98.6 million in the fourth quarter, down 0.3% year over year.
Total cost of services in the reported quarter was $108.6 million, up 7.3% year over year.
Gross profit came in at $54.8 million, which inched up 0.5% from the prior-year quarter. Gross margin was 33.6% of net revenues, down 140 bps year over year.
Selling, general and administrative expenses totaled $29.2 million, up 9% year over year. Operating income in the fourth quarter was $25.7 million, down 7.7% from the year-ago quarter. Operating margin was 15.7%, down 220 bps from the prior-year quarter.
Cash and cash equivalents as of Dec 31, 2019, amounted to $139.3 million, down 22.2% from the prior-year quarter.
Cumulative cash provided by operating activities at the end of the fourth quarter came in at $133.2 million, compared with $96.5 million reported in the year-ago quarter.
For 2020, the company anticipates revenues between $705 million and $715 million, indicating an improvement of 14.5-16.2% from prior year. The mid-point of $710 million is higher than the Zacks Consensus Estimate of $701.9 million.
Net income is expected in the band of $76-$80 million, suggesting growth of 10.1-15.9% from the previous year.
Adjusted EBITDA is expected in the range of $185-$192 million, suggesting growth of 12.8-17.1% from the year-ago comparable period.
HMS Holdings ended fourth-quarter 2019 on a weak note, wherein both earnings and revenues missed their respective Zacks Consensus Estimate. The stock continues to benefit from Analytical Services unit. Strong 2020 outlook also instills investor optimism in the stock.
However, cut throat competition in the U.S. medical cost containment space remains a concern. Moreover, the company witnessed contraction in both gross and operating margins in the quarter under review.
Currently, HMS Holdings carries a Zacks Rank #2 (Buy).
Earnings of Other MedTech Majors at a Glance
Some other top-ranked stocks that reported solid results this earning season are Stryker Corporation SYK, Accuray Incorporated ARAY and IDEXX Laboratories, Inc. IDXX. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker delivered fourth-quarter 2019 adjusted EPS of $2.49, outpacing the Zacks Consensus Estimate by 1.2%. Fourth-quarter reported revenues of $4.13 billion surpassed the Zacks Consensus Estimate by 0.7%. The company carries a Zacks Rank #2.
Accuray reported second-quarter fiscal 2020 adjusted earnings per share (EPS) of a penny, beating the Zacks Consensus Estimate of a loss of 7 cents. Net revenues of $98.8 million outpaced the Zacks Consensus Estimate by 0.3%. The company sports a Zacks Rank #1.
IDEXX Laboratories reported fourth-quarter 2019 adjusted EPS of $1.04, which beat the Zacks Consensus Estimate of 91 cents by 14.3%. Revenues were $605.4 million, surpassing the Zacks Consensus Estimate by 0.9%. The company carries a Zacks Rank of 2.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.7% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Stryker Corporation (SYK) : Free Stock Analysis Report
Accuray Incorporated (ARAY) : Free Stock Analysis Report
HMS Holdings Corp (HMSY) : Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research